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Abstract
OBJECTIVES: Lung transplantation (LTx) is the only effective treatment for end-stage lung disease. In rapidly deteriorating patients awaiting
transplant, supportive strategies for lung function allow only a short period of support and lung transplantation remains the definitive
therapy. An urgent transplant programme may reduce the waiting time, allowing lung transplantation in these patients.
METHODS: Since November 2010 a nation-wide urgent lung transplant programme has been established in Italy and patients on the
waiting list dependent on mechanical ventilation and/or extracorporeal lung support (ECLS) can be transplanted on an emergency basis
with the first available graft in the country. Results of the first 14 months of this programme are analysed here.
RESULTS: From November 2010 to December 2011, 28 patients (14 males, mean age 33.6 ± 14.4 years) were considered for urgent LTx.
Rapidly deteriorating lung function was supported with mechanical ventilation alone in 4 patients (14.3%), ECLS in 13 patients (46.4%) and
mechanical ventilation plus ECLS in the remaining 11 patients (39.3%). Three patients (10.7%) were excluded because of worsening condi-
tions, 3 patients (10.7%) while on the urgent listed and 22 patients (78.6%) underwent transplantation after 9.8 ± 6.2 days of being on the
urgent list. The 30-day mortality rate after LTx was 18%, and the 1-year survival rate was 71.4%.
CONCLUSIONS: The urgent lung transplant programme allowed transplantation in a significant percentage of prioritized patients with ac-
ceptable 30-day and 1-year mortality rates. An accurate selection of recipients may further improve the clinical impact of this programme,
reducing the ethical concerns about transplantation in high-risk patients.
Keywords: Lung transplantation • Urgent lung transplantation • Extracorporeal membrane • Oxygenation • Extracorporeal lung support •
Mechanical ventilation
INTRODUCTION
Lung transplantation (LTx) is the only effective treatment for end-
stage lung disease in selected patients [1]. Owing to a low graft
suitability rate, patients awaiting LTx suffer from a longer period
and a higher mortality rate while on the list, when compared with
data from other solid organ transplants. Furthermore, in contrast
to end-stage heart and kidney disease, long-term supportive strat-
egies are not available as a bridge to lung transplant for rapidly
deteriorating patients. Only short-term devices [such as mechan-
ical ventilation (MV) and extracorporeal lung support (ECLS)] can
be used and LTx remains the definitive therapy after a relatively
brief period of assistance.
Several strategies (the use of marginal grafts, the reconditioning
of grafts with poor function and from donation-after-cardiac-
death (DCD) donors, and living lobar transplant) have been devel-
oped to increase the number of transplants. These techniques
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may reduce but not eliminate the percentage of deteriorated
patients and urgent lung transplant remains the only effective
solution.
The aim of this study was to evaluate the first 14-month results
of the Italian Urgent Lung Transplant programme (IULTp).
MATERIALS ANDMETHODS
In October 2010, under the supervision of Centro Nazionale
Trapianti (CNT), all Italian lung transplant centres created and
agreed on a common protocol to identify patients requiring lung
transplant priority. From November 2010, the IULTp has been
started. Strict inclusion and exclusion criteria were adopted to
minimize the percentage of graft waste. Inclusion and exclusion
criteria are reported in Table 1. IULTp is reserved for young listed
patients requiring MV and/or ECLS with extracorporeal mem-
brane oxygenator (ECMO) or Novalung. Retransplantation is not
considered an exclusion criteria. Priority can last just 1 week and
can be renewed a maximum of twice. Therefore, the longest
period allowed to benefit from the IULTp is 3 weeks. All available
lungs in the country must be considered for urgent transplant first
and violations of inclusion/exclusion criteria can be considered in
selected cases upon CNT approval only.
Statistical analysis
Descriptive statistics are presented as means, standard deviations,
medians and ranges for continuous variables. Comparison
between groups were performed using χ2 and unequal variance
t-test as appropriate. Kaplan–Meier analysis was used to evaluate
long-term survival. Statistical analysis was performed using IBM®
SPSS Statistic®, Version 21.
RESULTS
From November 2010 till December 2011, 28 patients [14 males;
mean age 33.6 ± 14.4 years; body mass index (BMI) 17.6 ± 6.2]
entered IULTp. Indications for LTx were: cystic fibrosis (14 patients—
50%), idiopathic pulmonary fibrosis (9 patients—32%), Eisenmenger
syndrome (2 patients—7%), histiocytosis × (1 patient—4%) and graft
failure (2 patients—7%). Rapidly deteriorating lung function was
supported with MV alone in 4 patients (14%), ECLS in 13 patients
(47%) and MV plus ECLS in the remaining 11 patients (39%)
(Table 2). ECLS was accomplished through veno-venous ECMO in
22 patients and veno-arterial ECMO in 1 patient, respectively.
Among those, 3 patients (11%) died while on the urgent waiting
list and 3 patients (11%) were excluded because of worsening con-
ditions. After 9.8 ± 6.2 days (range: 2–23 days) on the urgent list,
22 patients (79%) underwent transplantation. Most patients (91%)
were on ECLS; MV was required on 12 patients (54.5%) (Table 3).
Donor characteristics are summarized in Table 3. Notably, optimal
grafts without reconditioned lungs were used. Twenty patients
(90%) received a double lung transplant (DLTx) and only two
patients received a single right graft (SLTx). Only three procedures
were performed off-pump, the remaining 19 were conducted on
extracorporeal support (14 standard cardiopulmonary by-pass
and 5 veno-venous ECMO). Median duration of post-transplant
MV and intensive care unit (ICU) stay were 120 h and 30 days, re-
spectively. Twelve patients (54.5%) needed ECMO after transplant
for a median duration of support of 2 days (Table 3). One patient
died on ECMO on postoperative day (POD) 18 and the remaining
11 patients recovered an acceptable pulmonary function, allowing
ECMO weaning after 4.9 ± 6.2 days (median 2 days). Overall
30-day mortality was 18% (4 patients). The causes of death were:
cerebral haemorrhage 1 patient (POD 17), sepsis 1 patient (POD
18), and multiorgan failure 2 patients (both on POD 2). All patients
who died were on ECLS pretransplant with three of them also re-
quiring pretransplant MV. The comparison between the subgroup
of patients dying (DCD) and surviving (no DCD) showed a longer
ECMO support after transplant in the DCD cohort (10.5 ± 9.8 vs
3.7 ± 4.3 days, P = 0.04). Although not statistically significant, post-
transplant ECMO was required in 100% of DCD patients versus
44% of those surviving. Donor characteristics were similar for the
two subgroups (Table 4) even if DCD patients received grafts from
slightly older donors (Table 5). Thirty-day, 6-month and 1-year
survival rates are 81.8, 76.2 and 71.4%, respectively (Fig. 1A).
Figure 1B shows survival curves according to the presence or
absence of pretransplant MV.
Table 6 shows the impact of pretransplant MV on clinical out-
comes. No differences were found in post-transplant ECMO inci-
dence, duration of MV, ICU stay and 30-day mortality. However,
the duration of post-transplant ECMO support was longer in venti-
lated patients (P = 0.012). The negative influence of MV was also
evident in the cohort of patients requiring pretransplant ECLS. In
fact, among preoperative ECLS patients, those who also needed
MV experienced a longer period of post-transplant ECMO
support and a tendency towards a higher 30-day mortality (3
patients out of 10, 30% vs 1 out of 10, 10%, P = 0.33) (Table 7).
Table 1: Inclusion and exclusion criteria for Italian Urgent
Lung Transplantation programme
Inclusion criteria Exclusion criteria
Age ≤50 y/o BMI < 18 or >30
MV and/or ECLS (except for DECAP®) Sepsis
Previous LTx waiting list Multiorgan failure
Haemorrhagic shock
Neurological damage
ECLS and/or MV >14 days
MV: mechanical ventilation, ECLS: extracorporeal lung support, BMI:
body mass index; LTx: lung transplantation.
Table 2: Pretransplant characteristics of patients enrolled
in Italian Urgent Lung Transplantation programme (n = 28)
Male 14 (50%)
Age (years) 33.6 ± 14.4, median 35
Body mass index 17.6 ± 6.2, median 18.4
Diagnosis
Cystic fibrosis 14 (50%) patients
Idiopathic pulmonary fibrosis 9 (32%) patients
Eisenmenger 2 (7%) patients
Histiocytosis X 1 (4%) patient
Graft failure 2 (7%) patients
Waiting list time (days) 202.9 ± 316, median 30
Infection 14 (50%)
Mechanical ventilation (MV) 4 (14.3%)
Extracorporeal lung support (ECLS) 13 (46.4%)
MV + ECLS 11 (39.3%)
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DISCUSSION
When compared with other solid organ transplants, LTx is charac-
terized by a smaller number of procedures performed worldwide
[1]. This is intimately related to the low rate of graft suitability [2].
Therefore, lung grafts are scarce and very precious resources.
Transplantation of severely critically ill patients may have a signifi-
cant impact on results and it may jeopardize short- and long-term
results. Ethical concerns arise when lungs are used on an urgent
basis because it implies that elective patients would suffer from a
longer wait on the list. This leads to a double consequence. First, a
more favourable risk/benefit ratio is lost, proportionately to the
severity status of the urgent recipient. Second, elective patients
are exposed to a longer waiting time and they may become
urgent cases because of the progression of their lung disease with
an increased risk at the time of transplantation. By contrast, the
absence of an urgent programme condemns critically ill recipients
to a fatal outcome. For all these reasons, careful evaluation and
strict selection of recipients are crucial.
These preliminary results of activation of the IULTp are encour-
aging. The interim analysis shows a good performance of
fulfilment (80%) of a national-based request. Despite initial con-
cerns, early and medium-term results are also acceptable, owing
to thoughtful and strict identification of those patients who may
obtain a survival benefit from transplant, despite the severity of
their pretransplant illness. Very recently, two papers described the
results of urgent LTx in Italy [3, 4]. However, in both these articles,
the study population was represented by patients with lung
transplantation on an urgent basis from 2009 to 2011. IULTp was
activated on 1 November 2010 and, before this urgent recipients
could not receive the graft automatically according to a well-
defined protocol. Thus, results reported by Pretagostini et al.
suffer from this bias. Moreover, the results are mainly focused on
request fulfilment and on the impact on on-list mortality. Our ana-
lysis considers patients who effectively entered IULTp and our
data analyses clinical results in terms of donor characteristics,
hospital mortality, impact of pretransplant MV and ECMO, and
medium-term survival.
According to the protocol, urgent transplants are reserved
for patients on MV and/or extracorporeal oxygenation. It is well
known that MV is associated with a higher risk of infection [3, 5],
diaphragmatic weakness [4, 6] and muscle wasting [5, 7], and that
they all may have a negative impact on the postoperative
outcome.
According to the International Registry [8], MV is a recognized
risk factor for 1-year mortality with a relative risk of 1.53. Singer
et al. [9] demonstrated that MV is associated with a significant
reduction of overall survival after LTx, increasing twice the risk of
death in the first 6 months. However, conditional survival to
6 months is not influenced by the presence/absence of MV.
Furthermore, MV seems to have a different impact even on early
post-transplant survival, depending on the underlying disease,
being the highest for cystic fibrosis or fibrotic lung disease
patients, and null for chronic obstructive pulmonary disease
patients. Data from United Network for Organ sharing [10]
showed that ventilated patients have both an adjusted and an un-
adjusted worse survival in comparison with unsupported patients.
In our series, ventilated patients showed the same incidence
of post-transplant ECMO implant when compared with those
not requiring pretransplant MV. However, the duration of post-
transplant circulatory support was significantly longer in MV
patients. This result is difficult to explain. It could be speculated
that the multiorgan detrimental effects of MV on those patients
may contribute to a general impairment requiring a longer period
of extracorporeal support. MV also seems to have an impact on
hospital mortality and its effect is even more evident when ECMO
is required. The negative prognostic effect of MV is maintained in
the medium term, although these differences do not reach statis-
tical significance probably due to the small cohort of patients
enrolled in the study.
As for MV, the role of ECMO before LTx is still debated, with a
reported 1-year post-transplant survival rate between 50 and 92%
[10–13]. Historically, ECMO support has been considered a contra-
indication in many lung transplant centres [14]. More recently,
extracorporeal support has become increasingly accepted and it
now has an important role in bridging critically ill patients to LTx
[15]. Lang et al. analysed data on 38 patients awaiting lung trans-
plant supported with ECMO. They showed that ECMO support is
a feasible bridging strategy, with acceptable clinical results [16].
Table 3: Transplanted patients’ characteristics (n = 22)
Pretransplant
Male 11 (50%)
Age (years) 38.4 ± 11.2, median 40.5
Body mass index 17.8 ± 6.7, median 18.5
Diagnosis
Cystic fibrosis 11 (50%)
Idiopathic pulmonary fibrosis 8 (36%)
Histiocytosis X 1 (5%)
Graft failure 2 (9%)
Mechanical ventilation (MV) alone 2 (9%)
Extracorporeal lung support (ECLS)
alone
10 (45.5%)
MV + ECLS 10 (45.5%)
Urgent WL time (days) 9.8 ± 6.2, median 5.5
Lung transplantation
DLTx 20 (90.9%)
SLTX (r) 2 (9.1%)
Post-transplant
ECMO 12 (54.5%)
ECMO duration (days) 6 ± 7.03, median 2
MV (h) 292.9 ± 326.8, median 120
Intensive care unit stay (days) 32 ± 24.9, median 30
Death
4 patients (18%) CVA: 1 patient (25%)
Sepsis: 1 patient (25%)
MOF: 2 patients (50%)
ECMO: extracorporeal membrane oxygenation; CVA: cerebro-vascular
accident; MOF: multiorgan failure; DLTx: double lung transplant; SLTx
(r): right lung transplant.
Table 4: Donors’ characteristics (n = 22)
Male 15 (68%)
Age (years) 43.5 ± 10.9, median 45
Body mass index 23.6 ± 3.3, median 23.7
History of smoke 9 (45%)
Mechanical ventilation (h) 75.4 ± 91.8, median 48
Intensive care unit stay (days) 3.9 ± 3.4, median 2
P/F (FiO2 100%)* 467.1 ± 72.5, median 460
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However, due to a limited number of reports and single-centre
series [17–18], further clinical experience on a larger population is
required to prove its safety and efficacy. A wider application
of ECLS techniques is the result of recent improvements in the
available devices, including polymethylpentene oxygenators [19],
heparin-coated circuits, double-lumen cannulas [13], pumpless
technologies [20] and new-generation centrifugal pumps.
Technological amelioration has made ECMO devices more reli-
able and the application of ECMO to reduce the need of MV has
been advocated, expanding its use in the clinical arena [21].
However, although anecdotal cases of prolonged ECMO support
before LTx [22] have been reported, ECLS should be still consid-
ered a short-term bridge. In a recently published series [9], each
day on ECMO increased the risk of death (mortality hazard ratio of
1.06) and a support longer than 14 days identified a high-
mortality subgroup of patients. This demonstrates that patients
should be transplanted as soon as possible while on ECMO to
reduce post-transplant mortality and morbidity. In this context, an
Table 5: Comparison between DCD (n = 4) and no DCD patients (n = 18)
DCD (n = 4) No DCD (n = 18) P-value
Pre-LTx
Age (years) 41.3 ± 10.6, median 41.5 37.7 ± 11.5, median 37.5 0.57
MV alone 0 patient (0%) 2 patients (11%) 0.66
ECLS alone 1 patient (25%) 9 patients (50%) 0.44
MV + ECLS 3 patients (75%) 7 patients (39%) 0.25
IULTp waiting time (days) 7.75 ± 7.5, median 4 8.1 ± 6.5, median 6 0.93
Colonization 1 patient (25%) 9 patients (50%) 0.44
Post-LTx
MV (h) 494.3 ± 225.7, median 504 255.2 ± 34.3, median 96 0.19
ICU stay (days) 25.8 ± 5.7, median 27.5 33.5 ± 27.6, median 32 0.59
ECMO 4 patients (100%) 8 patients (44%) 0.07
ECMO duration (days) 10.5 ± 9.8, median 10 3.7 ± 4.3, median 2 0.04
CPB 4 patients (100%) 15 patients (83%) 0.53
Donors
Age (years) 52.5 ± 9.9, median 55 41.6 ± 10.3, median 43.5 0.07
BMI 26.3 ± 5.5, median 26.3 23 ± 2.5, median 23.2 0.07
History of smoke 1 patient (25%) 9 patients (50%) 0.44
Cause of death CVA 2 patients (50%) other 2 patients (50%) CVA 7 patients (39%) trauma 7 patients (39%) other 4 patients (22%)
ICU stay (days) 1.75 ± 0.5, median 2 4.3 ± 3.6, median 3 0.18
MV (h) 42.5 ± 12.4, median 48 88.5 ± 107, median 48 0.41
P/F (FiO2 100%)* 461 ± 22.6, median 467 468.7 ± 82, median 453 0.86
MV: mechanical ventilation; ECLS: extracorporeal lung support; IULTp: Italian Urgent Lung Transplantation programme; ICU: intensive care unit; ECMO:
extracorporeal membrane oxygenation; BMI: body mass index; CPB: cardiopulmonary bypass.
*P/F (FiO2 100%): arterial oxygen concentration at 100% of inspired oxygen.
Figure 1: (A) Kaplan–Meier survival curve of IULTp patients; (B) Kaplan–Meier survival curve of ventilated (MV) and not ventilated (no MV) patients before LTx. IULTp:
Italian Urgent Lung Transplant Programme; MV: mechanical ventilation; LTx: lung transplantation.
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urgent lung transplant programme becomes crucial. In our experi-
ence, only 1 out of 10 unventilated ECMO-supported patients
died after lung transplant, suggesting that ECMO may be effective
and safe even in case of critically ill patients, if MV can be avoided.
Our results could have been influenced by several factors: the
type of ECMO used (veno venous configuration in all patients
except one), the most recent available technologies used with
polymethylpentene oxygenators in all cases and a limited dur-
ation of support (maximal duration 23 days).
Reports of urgent LTx results are scarce. Román et al. [23]
described the urgent LTx programme in Spain with dismal survival
rates of 47.9, 40.8 and 37.1% at 1, 3 and 5 years, respectively.
These results may be explained by the fact that this experience
refers to an older era characterized by a learning curve in the ap-
plication of new technologies. The indication for urgent listing in
this protocol was also different, including only patients on MV or
with life-threatening primary pulmonary hypertension without
mention on the use of ECMO. Better results were reported by
Saeressig et al. [24] on a single-centre cystic fibrosis population, in
France. Comparison between urgent and elective transplants did
not show any difference in terms of ICU length of stay, severity of
primary graft dysfunction, 1- and 2.5-year survival rates. However,
according to their protocol, MV and or ECMO were not essential
requirements for priority, and the percentage of ventilated or cir-
culatory assisted patients is not reported in the two groups. More
recently, Boussaud et al. [25] reported results of the French high-
emergency LTx (HELTx) programme from July 2007 to June 2008.
In this analysis, a poorer survival of HELTx has been shown, if com-
pared with outcomes of non-urgent transplants.
Further investigations including a larger group of lung recipients
and encompassing a longer period of time may better confirm
the positive preliminary results of our study. The limited sample
size does not allow meaningful statistical comparisons. We ac-
knowledge that the results are merely descriptive and a compari-
son with ‘elective’ lung transplant procedures during the same
period would have been useful to better demonstrate the safety
and efficacy of the IULTp.
In conclusion, the nation-wide Italian Urgent Lung Transplant
Programme allowed transplantation in a significant percentage
of patients with acceptable clinical results. An accurate selection
of recipients may further improve the clinical impact of this pro-
gramme, reducing the ethical concerns about transplantation in
high-risk patients.
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Table 7: Comparison between extracorporeal lung support (ECLS) patients (n = 10) and mechanical ventilation + ECLS patients
(n = 10)
ECLS (n = 10) MV + ECLS (n = 10) P-value
Urgent WL time (days) 6.6 ± 4.6, median 5 7.8 ± 7.1, median 5 0.7
ECMO post-LTx 6 patients (60%) 5 patients (50%) 0.68
ECMO duration (days) 2.16 ± 1.47, median 2 11.4 ± 8.4, median 14 0.002
MV post-LTx (h) 297.1 ± 326.8, median 120 240.3 ± 337.2, median 72 0.7
ICU stay (days) 31 ± 33.5, median 25 35.9 ± 15.3, median 32 0.7
DCD 1 patient (10%) 3 patients (30%) 0.33
MV: mechanical ventilation; ICU: intensive care unit; ECMO: extracorporeal membrane oxygenation; LTx: lung transplantation.
Table 6: Comparison between ventilated (n = 12) and not ventilated patients (n = 10)
MV (n = 12) No MV (n = 10) P-value
Urgent WL time (days) 9.2 ± 7.8, median 6 6.6 ± 4.6, median 5 0.22
ECMO post-LTx 6 patients (50%) 6 patients (60%) 0.67
ECMO duration (days) 9.8 ± 8.4, median 8.5 2.2 ± 1.5, median 2 0.012
MV post-LTx (h) 288.3 ± 346.7, median 96 297.1 ± 326.8, median 120 0.95
ICU stay (days) 32.1 ± 15.3, median 30 31 ± 33.5, median 25 0.93
DCD 3 patients (25%) 1 patients (10%) 0.43












M. Boffini et al. / Interactive CardioVascular and Thoracic Surgery 799
Downloaded from https://academic.oup.com/icvts/article-abstract/19/5/795/648990
by Azienda Ospedaliera Careggi user
on 01 February 2018
REFERENCES
[1] Boffini M, Ranieri VM, Rinaldi M. Lung transplantation: is it still an experi-
mental procedure? Curr Opin Crit Care 2010;16:53–61.
[2] Punch JD, Hayes DH, LaPorte FB, McBride V, Seely MS. Organ donation and
utilization in the United States, 1996–2005. Am J Transpl 2007;7:1327–38.
[3] Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit
Care Med 2002;165:867–903.
[4] Pretagostini R, Rizzato L, Ricci A, Puoti F, Peritore D, Nanni Costa A. Urgent
liver, heart, and lung transplantation programs in Italy: activities and evalu-
ation of outcomes. Transplant Proc 2013;45:2616–8.
[5] Pretagostini R, Peritore D, Rizzato L, Stabile D, D’Alessandro F,
Michelangeli G et al. Urgent lung transplantation national program: the
Italian experience. Transplant Proc 2013;45:2607–9.
[6] Vassilakopoulos T, Petrof BJ. Ventilator-induced diaphragmatic dysfunc-
tion. Am J Respir Crit Care Med 2004;169:336–41.
[7] Gruther W, Benesch T, Zorn C, Paternostro-Sluga T, Quittan M, Fialka-Moser
V et al. Muscle wasting in intensive care patients: ultrasound observation of
the M. quadriceps femoris muscle layer. J Rehabil Med 2008;40:185–9.
[8] Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI,
Dobbels F et al. The Registry of the International Society for Heart and
Lung Transplantation: 29th adult lung and heart-lung transplant
report-2012. J Heart Lung Transplant 2012;31:1073–86.
[9] Singer JP, Blanc PD, Hoopes C, Golden JA, Koff JL, Leard LE et al. The
impact of pretransplant mechanical ventilation on short- and long-term
survival after lung transplantation. Am J Transplant 2011;11:2197–204.
[10] Mason DP, Thuita L, Nowicki ER, Murthy SC, Pettersson GB, Blackstone
EH. Should lung transplantation be performed for patients in mechanical
respiratory support? The US experience. J Thorac Cardiovasc Surg 2010;
139:765–73.
[11] Crotti S, Iotti GA, Lissoni A, Bollato M, Zanierato M, Chierichetti M et al.
The organ allocation waiting time during extracorporeal bridge to lung
transplantation affects outcomes. Chest 2013;144:1018–25.
[12] Hammainen P, Schersten H, Lemstrom K, Riise GC, Kukkonen S, Sward K et al.
Usefulness of extracorporeal membrane oxygenation as a bridge to lung
transplantation: a descriptive study. J Heart Lung Transplant 2011;30:103–7.
[13] Bermudez CA, Rocha RV, Sappington PL, Toyoda J, Murray HN, Boujoukos
AJ. Initial experience with single cannulation for venovenous extracorpor-
eal oxygenation in adults. Ann Thorac Surg 2010;90:991–5.
[14] Orens JB, Estenne M, Arcasoy S, Conte JV, Corris P, Egan JJ et al.
International guidelines for the selection of lung transplant candidates:
2006 update—a consensus report from the Pulmonary Scientific Council
of the International Society for Heart and Lung Transplantation. J Heart
Lung Transplant 2006;25:745–55.
[15] Del Sorbo L, Boffini M, Rinaldi M, Ranieri VM. Bridging to lung transplant-
ation by extracorporeal support. Minerva Anestesiol 2012;78:243–50.
[16] Lang G, Taghavi S, Aigner C, Rényi-Vámos F, Jaksch P, Augustin V et al.
Primary lung transplantation after bridge with extracorporeal membrane
oxygenation: a plea for a shift in our paradigms for indications. Transplan-
tation 2012;93:729–36.
[17] Jurmann MJ, Haverich A, Demertzis S, Schaefers HJ, Wagner TO, Borst HG.
Extracorporeal membrane oxygenator as a bridge to lung transplant. Eur J
Cardiothorac Surg 1991;5:94–7.
[18] Jackson A, Cropper J, Pye R, Junius F, Malouf M, Glanville A. Use of extra-
corporeal membrane oxygenator as a bridge to primary lung transplant: 3
consecutive, successful cases and a review of the literature. J Heart Lung
Transplant 2008;27:348–52.
[19] Hartwig MG, Walczak R, Lin SS, Davis RD. Improved survival but marginal
allograft function in patients treated with extracorporeal membrane oxy-
genation after lung transplantation. Ann Thorac Surg 2012;93:366–71.
[20] Ricci D, Boffini M, Del Sorbo L, El Qarra S, Comoglio C, Ribezzo M et al.
The use of CO2 removal devices in patients awaiting lung transplantation:
an initial experience. Transplant Proc 2010;42:1255–8.
[21] Nosotti M, Rosso L, Tosi D, Palleschi A, Mendogni P, Nataloni IF et al.
Extracorporeal membrane oxygenation with spontaneous breathing as a
bridge to lung transplantation. Interact CardioVasc Thorac Surg 2013;16:
55–9.
[22] Iacono A, Groves S, Garcia J, Griffith B. Lung transplantation following 107
days of extracorporeal membrane oxygenation. Eur J Cardiothorac Surg
2010;37:969–71.
[23] Román A, Calvo V, Ussetti P, Borro JM, Lama R, Zurbano F et al. Urgent
lung transplantation in Spain. Transplant Proc 2005;37:3987–90.
[24] Saeressig MG, Pellau S, Sermet I, Souilamas R. Urgent lung transplantation
in cystic fibrosis patients: experience of a French center. Eur J Cardio-
thorac Surg 2011;40:e101–6.
[25] Boussaud V, Mal H, Trinquart L, Thabut G, Danner-Boucher I, Dromer C
et al. One-year experience with high-emergency lung transplantation in
France. Transplantation 2012;93:1058–63.
APPENDIX. CONFERENCE DISCUSSION
Dr J. Bekkers (Rotterdam, Netherlands): Waiting list mortality is, of course, a
serious problem in lung transplantation. The ultimate goal for an effective pro-
gramme is to provide end-stage lung failure patients with well-functioning
donor organs at the right time. For that purpose, many countries have systems
that prioritize patients who are in a deteriorating condition, such as the lung al-
location score used in the United States and more recently also adopted in
most European transplant countries.
In your presentation you describe the introduction of an urgent lung trans-
plant programme in Italy in 2010. And in the abstract, the objective for this pro-
gramme is to reduce the waiting list mortality for this kind of patient. But in
your results I don’t find an analysis of waiting list mortality. So my first question
is: what was the policy in Italy before 2010 for patients deteriorating on a
waiting list? Was there any urgency system then for those patients? And did you
indeed analyse whether the introduction of this system led to reduction of this
waiting list mortality?
Dr Boffini: In Italy the organization was quite complex because we have
three areas for organ allocation. Before November 2010, you could indicate
that you had an urgent patient, but every single centre could decide to keep
the donor and to go for transplant or to offer you the graft. So it wasn’t a system
that worked well, and we had the feeling that things should be changed. These
are very preliminary results and they are coming from a national database, so
they are not completed. We are looking into the issue that you raise, but I
haven’t got the answer at the moment.
Dr Bekkers: Then a second question is that in your programme only patients
on mechanical ventilation or on ECMO are accepted as urgent patients,
whereas other systems do have less strict criteria and also accept patients with
higher urgency who are deteriorating even as an outpatient or not yet on venti-
lation or ECMO. And because mechanical ventilation and ECMO are both
complex treatment options with increasing risk for patients, wouldn’t it be ad-
visable then to have a system to have patients get a priority status before they
end up on ventilation or ECMO? What’s your opinion about that?
Dr Boffini: The aim of the group was to be quite strict in the identification of
patients who may enter the programme, because in Italy we are suffering from
a severe decrease of donations, especially for thoracic organs. And the purpose
of this programme was to define the most critically ill patients, with an accept-
able risk/benefit ratio, trying not to impair the results. And for this reason we
excluded, for example, decapneization, and we included only ECMO and the
Novalung.
Dr Bekkers: So there is no priority given to patients not yet on ECMO or
ventilation?
Dr Boffini: No.
Dr W. Klepetko (Vienna, Austria): In the interests of time we have to move
forward, but I would like to add that you really can be congratulated for deliver-
ing such exciting good results for multicentre cooperation work.
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